Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 10,831 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Abnormalities Clear all
Recruiting No phase listed Observational

Sinus Disease in Young Children With Cystic Fibrosis

NCT06191640
View directory record Official record
Conditions
Cystic Fibrosis in Children, Cystic Fibrosis, Chronic Rhinosinusitis (Diagnosis), Olfactory Disorder, Olfactory Impairment
Interventions
Ivacaftor or elexacaftor/tezacaftor/ivacaftor
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
2 Years to 8 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
6
States / cities
Aurora, Colorado • Iowa City, Iowa • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 28, 2026, 10:13 AM EDT
Terminated Phase 2 Interventional Results available

Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT02029417
View directory record Official record
Conditions
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
cytarabine, omacetaxine mepesuccinate, decitabine, laboratory biomarker analysis
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
65 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Oct 28, 2026, 10:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease

NCT04255875
View directory record Official record
Conditions
Healthy, Sickle Cell Anemia
Interventions
Placebo, PF-07209326
Biological
Lead sponsor
Pfizer
Industry
Eligibility
16 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
16
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Fort Myers, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 28, 2026, 10:13 AM EDT
Recruiting No phase listed Observational

Discarded Bone Marrow for Hematology Research

NCT04671212
View directory record Official record
Conditions
Hemoglobinopathies
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2035
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 28, 2026, 10:13 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Natural History of Intestinal Inflammation in People With Primary Immune Dysregulations

NCT03278912
View directory record Official record
Conditions
Chronic Granulomatous Disease, Inflammatory Bowel Disease
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 28, 2026, 10:13 AM EDT
Terminated No phase listed Observational

The Ribavirin Pregnancy Registry

NCT00114712
View directory record Official record
Conditions
Birth Defects, Pregnancy Complications, Hepatitis C
Interventions
Not listed
Lead sponsor
Syneos Health
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2020
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 14, 2020 · Synced Oct 28, 2026, 10:13 AM EDT
Not listed Not applicable Interventional

Feasibility Study to Collect and Assess Safety Data for a Radiofrequency Microneedling Device for Electrocoagulation and Hemostasis of Soft Tissues for Dermatologic Conditions

NCT05987319
View directory record Official record
Conditions
Wrinkle, Fine Lines, Crepey Skin, Acne Scars, Active Acne, Enlarged Pores, Stretch Mark, Loose Skin
Interventions
RadioFrequency Microneedling Device
Device
Lead sponsor
Cynosure, Inc.
Industry
Eligibility
22 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Westford, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 28, 2026, 10:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of a 2-week Relaxing Music Intervention on Anxiety, Stress, and Gut Symptoms in Aerobic Exercisers

NCT04671628
View directory record Official record
Conditions
Gastrointestinal System--Abnormalities, Anxiety, Visceral Pain
Interventions
Relaxing music
Behavioral
Lead sponsor
Old Dominion University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 28, 2026, 10:13 AM EDT
Active, not recruiting Early Phase 1 Interventional

Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)

NCT05600907
View directory record Official record
Conditions
Chronic Granulomatous Disease, CGD
Interventions
JSP191
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 28, 2026, 10:13 AM EDT
Completed Not applicable Interventional Results available

Gerofit Exercise Intervention for Older Adults With Sickle Cell Disease (SICKLE-FIT Study)

NCT05714098
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Gerofit Exercise Program
Behavioral
Lead sponsor
Duke University
Other
Eligibility
40 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 28, 2026, 10:13 AM EDT
Completed No phase listed Observational

Rate of Progression in EYS Related Retinal Degeneration

NCT04127006
View directory record Official record
Conditions
Retinitis Pigmentosa, Eye Diseases
Interventions
Not listed
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
13
States / cities
San Francisco, California • Denver, Colorado • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 28, 2026, 10:13 AM EDT
Completed No phase listed Observational

Genetic and Physical Study of Childhood Nerve and Muscle Disorders

NCT01568658
View directory record Official record
Conditions
Muscular Dystrophies, Muscle Myopathies, Hereditary Spastic Paraplegias, Inherited Neuropathies, Inherited Neuromuscular Conditions
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
1 Day to 100 Years
Enrollment
2,586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 28, 2026, 10:13 AM EDT
Completed Not applicable Interventional

Physical Activity in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy

NCT00554489
View directory record Official record
Conditions
Leukemia
Interventions
exercise intervention
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years to 120 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 28, 2026, 10:13 AM EDT
Recruiting No phase listed Observational

Familial Investigations of Childhood Cancer Predisposition

NCT03050268
View directory record Official record
Conditions
Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML, BAP1 Tumor Predisposition Syndrome, Carney Complex, Choroid Plexus Carcinoma, Constitutional Mismatch Repair Deficiency Syndrome, Diamond-Blackfan Anemia, DICER1 Syndrome, Dyskeratosis Congenita, Emberger Syndrome, Familial Acute Myeloid Leukemia, Familial Adenomatous Polyposis, Fanconi Anemia, Familial Cancer, Familial Wilms Tumor, Familial Neuroblastoma, GIST, Hereditary Breast and Ovarian Cancer, Hereditary Paraganglioma-Pheochromocytoma Syndrome, Hodgkin Lymphoma, Juvenile Polyposis, Li-Fraumeni Syndrome, Lynch Syndrome, MDS, Melanoma Syndrome, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2, Neuroblastoma, Neurofibromatosis Type 1, Neurofibromatosis Type II, Nevoid Basal Cell Carcinoma Syndrome, Non Hodgkin Lymphoma, Noonan Syndrome and Other Rasopathy, Overgrowth Syndromes, Pancreatic Cancer, Peutz-Jeghers Syndrome, Pheochromocytoma/Paraganglioma, PTEN Hamartoma Tumor Syndrome, Retinoblastoma, Rhabdoid Tumor Predisposition Syndrome, Rhabdomyosarcoma, Rothmund-Thomson Syndrome, Tuberous Sclerosis, Von Hippel-Lindau Disease
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2037
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 28, 2026, 10:13 AM EDT
Completed Phase 3 Interventional

A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

NCT07155668
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
VRDN-003, Autoinjector
Drug · Device
Lead sponsor
Viridian Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
13
States / cities
Inglewood, California • Cape Coral, Florida • Kissimmee, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 28, 2026, 10:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Nonlinear Elasticity Mapping of Breast Masses

NCT04863443
View directory record Official record
Conditions
Breast Cancer
Interventions
Ultrasound
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2025
U.S. locations
2
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 28, 2026, 10:13 AM EDT
Completed Phase 1 Interventional

T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

NCT00080925
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
filgrastim, graft-versus-tumor induction therapy, rituximab, therapeutic allogeneic lymphocytes, cyclophosphamide, cyclosporine, cytarabine, doxorubicin hydrochloride, etoposide, fludarabine phosphate, prednisone, vincristine sulfate, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Oct 28, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis

NCT01684410
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Alpha-1 HC 100 mg, Placebo, Alpha-1 HC 200 mg
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Birmingham, Alabama • Denver, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 28, 2026, 10:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers

NCT03291782
View directory record Official record
Conditions
Gout
Interventions
D-0120
Drug
Lead sponsor
InventisBio Co., Ltd
Industry
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 28, 2026, 10:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of STAR-0215 in Healthy Adult Participants

NCT05477160
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
STAR-0215 (SC), Placebo (SC), STAR-0215 (IV), Placebo (IV)
Drug
Lead sponsor
Astria Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Oct 28, 2026, 10:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarker Monitoring in TP53 Mutation Carriers

NCT02289326
View directory record Official record
Conditions
Li-Fraumeni Syndrome, Hereditary Cancer Syndromes, TP53 Gene Germline Mutation Carrier
Interventions
Not listed
Lead sponsor
Scripps Health
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 28, 2026, 10:13 AM EDT
Completed Phase 1Phase 2 Interventional

AAVRh.10 Administered to Children With Late Infantile Neuronal Ceroid Lipofuscinosis

NCT01414985
View directory record Official record
Conditions
Late Infantile Neuronal Ceroid Lipofuscinosis, Batten Disease
Interventions
AAVrh.10CUCLN2
Biological
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
3 Years to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 28, 2026, 10:13 AM EDT
Recruiting No phase listed Observational

Bowel Continence Across the Lifespan in People With Spina Bifida

NCT07390318
View directory record Official record
Conditions
Spina Bifida, Neurogenic Bowel, Bowel Incontinence
Interventions
Retrograde Enema, Antegrade Enema
Procedure
Lead sponsor
David Chu
Other
Eligibility
5 Years and older
Enrollment
943 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 28, 2026, 10:13 AM EDT
Recruiting Not applicable Interventional

Trajectories of Change in Tourette Syndrome

NCT06679790
View directory record Official record
Conditions
Tourette Syndrome, Tic Disorders
Interventions
Comprehensive Behavioral Intervention for Tics
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 28, 2026, 10:13 AM EDT